Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Analysts at William Blair issued their FY2027 EPS estimates for Vigil Neuroscience in a research note issued to investors on Thursday, May 22nd. William Blair analyst M. Minter expects that the company will post earnings of ($1.78) per share for the year. William Blair has a "Hold" rating on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share.
Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04.
VIGL has been the subject of a number of other reports. Mizuho downgraded shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. Citizens Jmp cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Wedbush downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and decreased their target price for the stock from $13.00 to $8.00 in a research report on Thursday, May 22nd. Guggenheim set a $8.00 price target on Vigil Neuroscience and gave the company a "neutral" rating in a report on Thursday, May 22nd. Finally, JMP Securities reiterated a "market perform" rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. Ten equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $10.80.
Get Our Latest Stock Analysis on Vigil Neuroscience
Vigil Neuroscience Price Performance
Shares of Vigil Neuroscience stock traded up $0.01 during midday trading on Friday, hitting $7.89. The company had a trading volume of 616,770 shares, compared to its average volume of 642,713. Vigil Neuroscience has a 1-year low of $1.31 and a 1-year high of $7.95. The business's 50 day simple moving average is $2.43 and its two-hundred day simple moving average is $2.35. The stock has a market cap of $368.01 million, a PE ratio of -3.83 and a beta of 1.90.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BVF Inc. IL grew its stake in shares of Vigil Neuroscience by 121.3% in the 1st quarter. BVF Inc. IL now owns 4,013,633 shares of the company's stock valued at $7,144,000 after purchasing an additional 2,200,000 shares during the period. Aberdeen Group plc grew its position in Vigil Neuroscience by 226.3% in the first quarter. Aberdeen Group plc now owns 1,724,520 shares of the company's stock valued at $3,070,000 after acquiring an additional 1,196,048 shares during the period. Blair William & Co. IL raised its stake in Vigil Neuroscience by 219.1% during the first quarter. Blair William & Co. IL now owns 1,033,577 shares of the company's stock worth $1,840,000 after acquiring an additional 709,677 shares in the last quarter. Woodline Partners LP raised its stake in Vigil Neuroscience by 239.1% during the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company's stock worth $831,000 after acquiring an additional 344,614 shares in the last quarter. Finally, 683 Capital Management LLC lifted its holdings in shares of Vigil Neuroscience by 24.3% during the first quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company's stock valued at $3,097,000 after acquiring an additional 340,000 shares during the period. Institutional investors own 83.64% of the company's stock.
Vigil Neuroscience Company Profile
(
Get Free Report)
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Featured Articles
Before you consider Vigil Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vigil Neuroscience wasn't on the list.
While Vigil Neuroscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
